TP53 and cancer: Various authors have investigated the role of different types of TP53 mutations in human cancer, but the results remain controversial.13,30-33 In the present study, we consider the surrogates of missense and null mutations separately and propose a new classification based on p53 IHC expression: null (0%), low (0.1%-49%) and high (≥50%).